Mymetics Corp (MYMX)

[Work Harder]

This is why the Nih does this crap

Open Orphan Says Strategic Review Underway To Seek To Monetise 49% Stake In Imutex

https://www.reuters.com/article/brief-open-orphan-says-strategic-review/brief-open-orphan-says-strategic-review-underway-to-seek-to-monetise-49-stake-in-imutex-idUSFWN2E103A

https://www.independent.ie/business/open-orphan-raises-63m-funds-through-share-placing-38915853.html

http://imutex.com/index.php/ags-v/

http://imutex.com/index.php/about/

Mr. Duncan is an investment professional with over 30 years’ experience in trading, principal transactions and early-stage venture investing. He began his career as a trader at Goldman Sachs in 1987, moving to Nomura, Credit Suisse and Mizuho, leading teams conducting principal investment activities. He has been an active angel investor since 2006, focusing on equity investments in promising, early-stage biotechnology companies, including Infirst Healthcare Limited, Pharmajet Ltd, Peptcell Limited and Curemark LLC. He sits on the board of each of his portfolio companies. He co-founded Rush Foundation in 2010, a charity focused on funding innovative solutions in the fight against the HIV pandemic in sub-Saharan Africa. Kim holds a BS in Electrical and Electronics Engineering from Yale University, a MS in Biotechnology from Georgetown University and a MS in Pharmacology and Physiology from Georgetown University.